CoChat

The Immune System in Cushing’s Syndrome

Open access
Hasenmajer, Valeria, Sbardella, Emilia, Sciarra, Francesca, Minnetti, Marianna, Isidori, Andrea M., Venneri, Mary Anna · 2020 · Trends in Endocrinology & Metabolism
Cited by 147

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Cushing's syndrome (CS), or chronic hypercortisolism, induces a variety of alterations in the immune system, often leading to severe clinical complications such as sepsis and opportunistic infections. Prolonged exposure to high levels of glucocorticoids (GC), changes in the circadian rhythm, and the comorbidities associated therewith all combine to cause profound changes in the immune profile of affected patients. While traditionally associated with generalized immune suppression, such changes actually comprise a much more complex scenario, sharing traits with chronic inflammatory disorders. Persistently increased levels of interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNFα) and adipose tissue infiltration by immune cells lead to a chronic, nonresolving, inflammatory state. The combination of low-grade inflammation and selectively impaired immune response is thought to play a major role in the pathogenesis of clinical complications of CS, including diabetes, lipodystrophy, visceral adiposity, atherosclerosis, osteoporosis, and cognitive impairment. This dysregulation also explains rebound phenomena when CS is treated, involving new clinical complications sustained by an excessive immune response and autoimmunity. The aim of this review is to summarize the available evidence on the immune system in chronic hypercortisolism, while describing the main mechanisms of immune derangement and their role in the increased mortality and morbidity seen in this complex disease. A better understanding of immune system alterations in CS could help improve risk stratification, offer novel biomarkers, and provide the basis for more tailored therapies and post-remission follow-up.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.tem.2020.04.004

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 92

  1. Vitale, 2017, Pituitary magnetic resonance imaging in Cushing's disease, Endocrine, 55, 691, 10.1007/s12020-016-1038-y · DOI
  2. Isidori, 2006, Ectopic ACTH syndrome, Front. Horm. Res., 35, 143, 10.1159/000094323 · DOI
  3. Isidori, 2015, Conventional and nuclear medicine imaging in ectopic Cushing's syndrome: a systematic review, J. Clin. Endocrinol. Metab., 100, 3231, 10.1210/JC.2015-1589 · DOI · Paper page
  4. Storr, 2004, Prepubertal Cushing's disease is more common in males, but there is no increase in severity at diagnosis, J. Clin. Endocrinol. Metab., 89, 3818, 10.1210/jc.2003-031531 · DOI · Paper page
  5. Alexandraki, 2009, The prevalence and characteristic features of cyclicity and variability in Cushing's disease, Eur. J. Endocrinol., 160, 1011, 10.1530/EJE-09-0046 · DOI · Paper page
  6. Steffensen, 2010, Epidemiology of Cushing's syndrome, Neuroendocrinology, 92, 1, 10.1159/000314297 · DOI · Paper page
  7. Pivonello, 2016, Complications of Cushing's syndrome: state of the art, Lancet Diabetes Endocrinol., 4, 611, 10.1016/S2213-8587(16)00086-3 · DOI · Paper page
  8. Isidori, 2015, Mechanisms in endocrinology: the spectrum of haemostatic abnormalities in glucocorticoid excess and defect, Eur. J. Endocrinol., 173, R101, 10.1530/EJE-15-0308 · DOI
  9. Mazziotti, 2016, Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines, Endocrine, 54, 603, 10.1007/s12020-016-1146-8 · DOI
  10. Graversen, 2012, Mortality in Cushing's syndrome: a systematic review and meta-analysis, Eur. J. Intern. Med., 23, 278, 10.1016/j.ejim.2011.10.013 · DOI
  11. Clayton, 2011, Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature, J. Clin. Endocrinol. Metab., 96, 632, 10.1210/jc.2010-1942 · DOI · Paper page
  12. Pivonello, 2016, Metabolic alterations and cardiovascular outcomes of cortisol excess, Front. Horm. Res., 46, 54, 10.1159/000443864 · DOI
  13. Sbardella, 2018, Cardiovascular features of possible autonomous cortisol secretion in patients with adrenal incidentalomas, Eur. J. Endocrinol., 178, 501, 10.1530/EJE-17-0986 · DOI · Paper page
  14. Valassi, 2019, High mortality within 90 days of diagnosis in patients with Cushing's syndrome: results from the ERCUSYN registry, Eur. J. Endocrinol., 181, 461, 10.1530/EJE-19-0464 · DOI · Paper page
  15. Lionakis, 2003, Glucocorticoids and invasive fungal infections, Lancet, 362, 1828, 10.1016/S0140-6736(03)14904-5 · DOI · Paper page
  16. Graham, 1984, Opportunistic infections in endogenous Cushing's syndrome, Ann. Intern. Med., 101, 334, 10.7326/0003-4819-101-3-334 · DOI · Paper page
  17. Ejaz, 2011, Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center Experience, Cancer, 117, 4381, 10.1002/cncr.26029 · DOI · Paper page
  18. Ilias, 2005, Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health, J. Clin. Endocrinol. Metab., 90, 4955, 10.1210/jc.2004-2527 · DOI · Paper page
  19. Sarlis, 2000, Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin, J. Clin. Endocrinol. Metab., 85, 42
  20. Isidori, 2006, The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up, J. Clin. Endocrinol. Metab., 91, 371, 10.1210/jc.2005-1542 · DOI · Paper page
  21. Dimopoulos, 1992, Paraneoplastic Cushing's syndrome as an adverse prognostic factor in patients who die early with small cell lung cancer, Cancer, 69, 66, 10.1002/1097-0142(19920101)69:1<66::AID-CNCR2820690113>3.0.CO;2-2 · DOI
  22. Scheffel, 2010, Invasive fungal infections in endogenous Cushing's syndrome, Infect. Dis. Rep., 2
  23. Fareau, 2007, Hypercortisolemia and infection, Infect. Dis. Clin. N. Am., 21, 639, 10.1016/j.idc.2007.06.001 · DOI
  24. van Halem, 2017, Characteristics and mortality of pneumocystis pneumonia in patients with Cushing's syndrome: a plea for timely initiation of chemoprophylaxis, Open Forum Infect. Dis., 4, 10.1093/ofid/ofx002 · DOI
  25. Long, 2020, High risk of activation of latent tuberculosis infection in rheumatic disease patients, Infect. Dis. (Lond.), 52, 80, 10.1080/23744235.2019.1682187 · DOI
  26. Colao, 2000, Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease, Clin. Endocrinol., 53, 13, 10.1046/j.1365-2265.2000.01018.x · DOI · Paper page
  27. Takasu, 1993, Development of autoimmune thyroid dysfunction after bilateral adrenalectomy in a patient with Carney's complex and after removal of ACTH-producing pituitary adenoma in a patient with Cushing's disease, J. Endocrinol. Investig., 16, 697, 10.1007/BF03348914 · DOI
  28. Takasu, 1990, Exacerbation of autoimmune thyroid dysfunction after unilateral adrenalectomy in patients with Cushing's syndrome due to an adrenocortical adenoma, N. Engl. J. Med., 322, 1708, 10.1056/NEJM199006143222404 · DOI · Paper page
  29. da Mota, 2011, Overt immune dysfunction after Cushing's syndrome remission: a consecutive case series and review of the literature, J. Clin. Endocrinol. Metab., 96, E1670, 10.1210/jc.2011-1317 · DOI · Paper page
  30. Marino, 2005, Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves, J. Endocrinol. Investig., 28, 280, 10.1007/BF03345386 · DOI
  31. Ueland, 2001, Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis, Eur. J. Endocrinol., 145, 685, 10.1530/eje.0.1450685 · DOI · Paper page
  32. Aranda, 2017, Circulatory immune cells in Cushing syndrome: bystanders or active contributors to atherometabolic injury? A study of adhesion and activation of cell surface markers, Int. J. Endocrinol., 2017, 2912763, 10.1155/2017/2912763 · DOI
  33. Aranda, 2018, Translational evidence of prothrombotic and inflammatory endothelial damage in Cushing syndrome after remission, Clin. Endocrinol., 88, 415, 10.1111/cen.13521 · DOI
  34. Masri-Iraqi, 2014, Elevated white blood cell counts in Cushing's disease: association with hypercortisolism, Pituitary, 17, 436, 10.1007/s11102-013-0522-0 · DOI
  35. Jablonska, 2017, The regulation of pre-metastatic niche formation by neutrophils, Oncotarget, 8, 112132, 10.18632/oncotarget.22792 · DOI · Paper page
  36. Nakagawa, 1998, Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes, Circulation, 98, 2307, 10.1161/01.CIR.98.21.2307 · DOI · Paper page
  37. Ronchetti, 2018, How glucocorticoids affect the neutrophil life, Int. J. Mol. Sci., 19, 10.3390/ijms19124090 · DOI · Paper page
  38. Nakagawa, 1999, The effect of glucocorticoids on the expression of L-selectin on polymorphonuclear leukocyte, Blood, 93, 2730, 10.1182/blood.V93.8.2730 · DOI · Paper page
  39. Ricci, 2017, Role of the glucocorticoid-induced leucine zipper gene in dexamethasone-induced inhibition of mouse neutrophil migration via control of annexin A1 expression, FASEB J., 31, 3054, 10.1096/fj.201601315R · DOI
  40. Bergstrom, 2017, Annexin A1 in blood mononuclear cells from patients with coronary artery disease: its association with inflammatory status and glucocorticoid sensitivity, PLoS One, 12, 10.1371/journal.pone.0174177 · DOI
  41. Perretti, 2009, Exploiting the Annexin A1 pathway for the development of novel anti-inflammatory therapeutics, Br. J. Pharmacol., 158, 936, 10.1111/j.1476-5381.2009.00483.x · DOI · Paper page
  42. Bergquist, 2015, Impairment of neutrophilic glucocorticoid receptor function in patients treated with steroids for septic shock, Intensive Care Med. Exp., 3, 59, 10.1186/s40635-015-0059-9 · DOI
  43. Tripodi, 2017, Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors, Endocrine, 56, 298, 10.1007/s12020-016-1027-1 · DOI
  44. Jurberg, 2018, Neuroendocrine control of macrophage development and function, Front. Immunol., 9, 1440, 10.3389/fimmu.2018.01440 · DOI
  45. Aranda, 2015, Long-term remission and recurrence rate in a cohort of Cushing's disease: the need for long-term follow-up, Pituitary, 18, 142, 10.1007/s11102-014-0567-8 · DOI
  46. Getting, 2002, Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis, Arthritis Rheum., 46, 2765, 10.1002/art.10526 · DOI · Paper page
  47. Andersen, 2017, Melanocortin 2, 3 and 4 receptor gene expressions are downregulated in CD8(+) T cytotoxic lymphocytes and CD19(+) B lymphocytes in rheumatoid arthritis responding to TNF-alpha inhibition, Scand. J. Immunol., 86, 31, 10.1111/sji.12555 · DOI
  48. Getting, 2008, A role for MC3R in modulating lung inflammation, Pulm. Pharmacol. Ther., 21, 866, 10.1016/j.pupt.2008.09.004 · DOI
  49. Leoni, 2008, Inflamed phenotype of the mesenteric microcirculation of melanocortin type 3 receptor-null mice after ischemia-reperfusion, FASEB J., 22, 4228, 10.1096/fj.08-113886 · DOI
  50. Norman, 2003, ACTH and alpha-MSH inhibit leptin expression and secretion in 3T3-L1 adipocytes: model for a central-peripheral melanocortin-leptin pathway, Mol. Cell. Endocrinol., 200, 99, 10.1016/S0303-7207(02)00410-0 · DOI
  51. Roerink, 2017, Increased adipocyte size, macrophage infiltration, and adverse local adipokine profile in perirenal fat in Cushing's syndrome, Obesity (Silver Spring), 25, 1369, 10.1002/oby.21887 · DOI
  52. Lee, 2019, Active Cushing disease is characterized by increased adipose tissue macrophage presence, J. Clin. Endocrinol. Metab., 104, 2453, 10.1210/jc.2018-02552 · DOI
  53. Isidori, 2002, Response of serum macrophage migration inhibitory factor levels to stimulation or suppression of the hypothalamo-pituitary-adrenal axis in normal subjects and patients with Cushing's disease, J. Clin. Endocrinol. Metab., 87, 1834
  54. Eddy, 2014, Glucocorticoids regulate natural killer cell function epigenetically, Cell. Immunol., 290, 120, 10.1016/j.cellimm.2014.05.013 · DOI
  55. Misale, 2018, Chromatin organization as an indicator of glucocorticoid induced natural killer cell dysfunction, Brain Behav. Immun., 67, 279, 10.1016/j.bbi.2017.09.004 · DOI
  56. Morgan, 2017, Distinct effects of dexamethasone on human natural killer cell responses dependent on cytokines, Front. Immunol., 8, 432, 10.3389/fimmu.2017.00432 · DOI
  57. Quatrini, 2018, Endogenous glucocorticoids control host resistance to viral infection through the tissue-specific regulation of PD-1 expression on NK cells, Nat. Immunol., 19, 954, 10.1038/s41590-018-0185-0 · DOI
  58. Kronfol, 1996, Immune regulation in Cushing's syndrome: relationship to hypothalamic-pituitary-adrenal axis hormones, Psychoneuroendocrinology, 21, 599, 10.1016/S0306-4530(96)00021-2 · DOI
  59. Masera, 1999, Natural killer cell activity in the peripheral blood of patients with Cushing's syndrome, Eur. J. Endocrinol., 140, 299, 10.1530/eje.0.1400299 · DOI
  60. Venneri, 2018, Circadian rhythm of glucocorticoid administration entrains clock genes in immune cells: a DREAM trial ancillary study, J. Clin. Endocrinol. Metab., 103, 2998, 10.1210/jc.2018-00346 · DOI · Paper page
  61. Minnetti, M. et al. Fixing the broken clock in adrenal disorders. Focus on glucocorticoids and chronotherapy. J. Endocrinol. (in press)
  62. Gadkari, 2018, Transcript- and protein-level analyses of the response of human eosinophils to glucocorticoids, Sci. Data, 5, 180275, 10.1038/sdata.2018.275 · DOI
  63. Wu, 2011, Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis, Science, 332, 243, 10.1126/science.1201475 · DOI · Paper page
  64. Lee, 2017, The eosinophil count tends to be negatively associated with levels of serum glucose in patients with adrenal Cushing syndrome, Endocrinol. Metab. (Seoul), 32, 353, 10.3803/EnM.2017.32.3.353 · DOI
  65. Oppong, 2013, Molecular mechanisms of glucocorticoid action in mast cells, Mol. Cell. Endocrinol., 380, 119, 10.1016/j.mce.2013.05.014 · DOI
  66. Vetillard, 2018, Glucocorticoid-induced leucine zipper: fine-tuning of dendritic cells function, Front. Immunol., 9, 1232, 10.3389/fimmu.2018.01232 · DOI
  67. Barahona, 2009, Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing's syndrome, J. Clin. Endocrinol. Metab., 94, 3365, 10.1210/jc.2009-0766 · DOI · Paper page
  68. Valassi, 2012, Adipokines and cardiovascular risk in Cushing's syndrome, Neuroendocrinology, 95, 187, 10.1159/000330416 · DOI · Paper page
  69. Urwyler, 2017, Interleukin-1 antagonism decreases cortisol levels in obese individuals, J. Clin. Endocrinol. Metab., 102, 1712, 10.1210/jc.2016-3931 · DOI · Paper page
  70. Geer, 2014, Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism, Endocrinol. Metab. Clin. N. Am., 43, 75, 10.1016/j.ecl.2013.10.005 · DOI · Paper page
  71. Oliveira, 2020, Osteoporosis and osteoarthritis are two sides of the same coin paid for obesity, Nutrition, 70, 110486, 10.1016/j.nut.2019.04.001 · DOI
  72. De Larichaudy, 2012, TNF-alpha- and tumor-induced skeletal muscle atrophy involves sphingolipid metabolism, Skelet. Muscle, 2, 2, 10.1186/2044-5040-2-2 · DOI · Paper page
  73. Crescioli, 2012, Inflammatory response in human skeletal muscle cells: CXCL10 as a potential therapeutic target, Eur. J. Cell Biol., 91, 139, 10.1016/j.ejcb.2011.09.011 · DOI
  74. Savino, 2016, Hormonal control of T-cell development in health and disease, Nat. Rev. Endocrinol., 12, 77, 10.1038/nrendo.2015.168 · DOI
  75. Kovalovsky, 2000, Molecular mechanisms and Th1/Th2 pathways in corticosteroid regulation of cytokine production, J. Neuroimmunol., 109, 23, 10.1016/S0165-5728(00)00298-8 · DOI
  76. Banuelos, 2016, BCL-2 protects human and mouse Th17 cells from glucocorticoid-induced apoptosis, Allergy, 71, 640, 10.1111/all.12840 · DOI
  77. Chen, 2004, Differential response of murine CD4+CD25+ and CD4+CD25− T cells to dexamethasone-induced cell death, Eur. J. Immunol., 34, 859, 10.1002/eji.200324506 · DOI · Paper page
  78. Suarez, 2006, Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids, Ann. Rheum. Dis., 65, 1512, 10.1136/ard.2005.049924 · DOI
  79. Pandolfi, 2013, Regulatory and effector T-cells are differentially modulated by dexamethasone, Clin. Immunol., 149, 400, 10.1016/j.clim.2013.09.008 · DOI
  80. Kasper, 2016, Empowering regulatory T cells in autoimmunity, Trends Mol. Med., 22, 784, 10.1016/j.molmed.2016.07.003 · DOI
  81. Gudbrandsdottir, 2018, Effects of rituximab and dexamethasone on regulatory and proinflammatory B-cell subsets in patients with primary immune thrombocytopenia, Eur. J. Haematol., 100, 45, 10.1111/ejh.12978 · DOI
  82. Cupps, 1985, Effects of in vitro corticosteroids on B cell activation, proliferation, and differentiation, J. Clin. Invest., 75, 754, 10.1172/JCI111757 · DOI · Paper page
  83. Cushing, 1932, Further concerning a parasympathetic center in the interbrain: VII. The effect of intraventricularly-injected histamine, Proc. Natl. Acad. Sci. U. S. A., 18, 500, 10.1073/pnas.18.7.500 · doi:10.1073/pnas.18.7.500
  84. Singer, 2016, The new sepsis consensus definitions (Sepsis-3): the good, the not-so-bad, and the actually-quite-pretty, Intensive Care Med., 42, 2027, 10.1007/s00134-016-4600-4 · DOI
  85. Warny, 2018, Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study, PLoS Med., 15, 10.1371/journal.pmed.1002685 · DOI · Paper page
  86. Bermejo-Martin, 2018, Shared features of endothelial dysfunction between sepsis and its preceding risk factors (aging and chronic disease), J. Clin. Med., 7, 10.3390/jcm7110400 · DOI
  87. Drifte, 2013, Innate immune functions of immature neutrophils in patients with sepsis and severe systemic inflammatory response syndrome, Crit. Care Med., 41, 820, 10.1097/CCM.0b013e318274647d · DOI · Paper page
  88. Rubio, 2019, Current gaps in sepsis immunology: new opportunities for translational research, Lancet Infect. Dis., 19, e422, 10.1016/S1473-3099(19)30567-5 · DOI · Paper page
  89. Chaudhary, 2017, Association of baseline steroid use with long-term rates of infection and sepsis in the REGARDS cohort, Crit. Care, 21, 185, 10.1186/s13054-017-1767-1 · DOI
  90. Venkatesh, 2018, Long-term outcomes of the ADRENAL trial, N. Engl. J. Med., 378, 1744, 10.1056/NEJMc1803563 · DOI
  91. Fang, 2019, Association of corticosteroid treatment with outcomes in adult patients with sepsis: a systematic review and meta-analysis, JAMA Intern. Med., 179, 213, 10.1001/jamainternmed.2018.5849 · DOI · Paper page
  92. Venkatesh, 2019, Hydrocortisone compared with placebo in patients with septic shock satisfying the sepsis-3 diagnostic criteria and APROCCHSS study inclusion criteria: a post hoc analysis of the ADRENAL trial, Anesthesiology, 131, 1292, 10.1097/ALN.0000000000002955 · DOI

Cited by

See all 147

Metadata

Authors
Hasenmajer, V., Sbardella, E., Sciarra, F., Minnetti, M., Isidori, A. M., & Venneri, M. A.
Venue
Trends in Endocrinology & Metabolism
Publisher
Elsevier BV
Published
2020-09
Volume
31
Issue
9
Pages
655-669
ISSN
1043-2760 (ISSN-L)
OpenAlex
W3023302320
Cited by
147
References
8
FWCI
4.73
Type
journal article
Language
en
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
Ministero dell’Istruzione, dell’Università e della Ricerca

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.